Home / Diabetes In Control (page 536)

Diabetes In Control

Berries Help to Preserve Memory

Berries such as blueberries and strawberries are high in anthocyanidins, a type of flavonoid antioxidant, which has been shown in previous studies to improve cognition. Analyzed data collected in the Nurses’ Health Study found that women who consumed 2 or more servings of strawberries and blueberries each week experienced a …

Read More »

New York Plans a Ban on Big Sizes of Sugary Drinks

New York City plans to enact a far-reaching ban on the sale of large sodas and other sugary drinks at restaurants, movie theaters and street carts. The proposed ban would affect virtually the entire menu of popular sugary drinks found in delis, fast-food franchises and even sports arenas, from energy …

Read More »

Plain Water over Sodas Lowers Risk of Developing Diabetes

The results, based on more than 80,000 women followed for more than a decade, suggest that adding water to the sugary beverages a person drinks throughout the day won’t make a difference, but replacing sweet drinks with water could help stave off the metabolic disorder. The amount of water women …

Read More »

The EmPower Diabetes Emergency Plan

EmPower

ACE and Lilly Diabetes have launched the “EmPower Diabetes Emergency Plan” with comprehensive tips to help people with diabetes prepare for emergencies such as natural disasters or even extended power outages. Every patient with diabetes needs to be prepared for the unexpected.

Read More »

Accu-Chek-Glooko

Glooko

  Accu-Chek-Glooko Roche Diabetes Care and Glooko, Inc. join forces to provide ACCU-CHEK meter users an easy solution to download their meter readings directly into their Apple iPhone® or iPod touch. The new Glooko IR Adapter connects to the Glooko MeterSync Cable to download blood glucose readings from ACCU-CHEK meters …

Read More »

Janssen Submits NDA for Canagliflozin

Janssen Submits NDA for Canagliflozin  Janssen Research & Development, LLC has submitted a New Drug Application (NDA) to the FDA seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

Read More »